Summary by Moomoo AI
Microport Medical Science Co., Ltd. announced its unaudited interim performance for the six months ended June 30, 2024, with revenue of 558,702 thousand US dollars, an increase of 17.0% compared to the same period last year (excluding the impact of exchange rates). Gross profit was 330,580 thousand US dollars, an increase of 14.6%, while the period loss decreased from 219,921 thousand US dollars to 106,674 thousand US dollars, a decrease of 51.5%. The loss attributable to equity shareholders of the company was 96,830 thousand US dollars, a decrease of 40.5%. The basic loss per share was 5.29 cents, diluted to 5.63 cents. The adjusted net loss, in accordance with non-Hong Kong financial reporting standards, was 68,432 thousand US dollars, a decrease of 63.1%. The company maintains a strong capital structure and actively manages working capital and financial resources. During the period, the company and its subsidiaries had a total of 6,987 employees worldwide, including 1,792 overseas employees. The company is committed to providing a diversified product portfolio and implementing a global strategy to enhance its core competitiveness.